Vimarsana
Biggest News Aggregation in the World

Only Recombinant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Only Recombinant. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Only Recombinant Today - Breaking & Trending Today

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 rADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura cTTP - Vimarsana News

Takeda Receives Positive CHMP Opinion for Recombinant ADAMTS13 rADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura cTTP

Published: January 1, 2024

Takeda TSE4502NYSETAK today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has recommended the approval under exceptional circumstances of recombinant ADAMTS13 rADAMTS13 for the treatment of ADAMTS13 deficiency in children and adult patients with cTTP.

Source: businesswireindia.com
Related Topics:
United StatesKremer HovingaJun SaitoVan DorlandThromb HaemostTakeda Pharmaceutical Company LimitedExchange CommissionJapanese Ministry Of HealthEuropean Medicines AgencyEuropean CommissionTreatment OptionsDrug AdministrationEuropean UnionFranchise Global Program Leader At TakedaCommittee For Medicinal Products Human UsePotentially Fatal Blood Clotting DisorderLimited Treatment OptionsMortality RateOnly RecombinantReplacement TherapyOpinion BasedIncluding ResultsFirst RandomizedCrossover PhaseMedicinal Products
FDA Approves Adzynma for Congenital Thrombotic Thrombocytopenic Purpura - Vimarsana News

FDA Approves Adzynma for Congenital Thrombotic Thrombocytopenic Purpura

Published: November 9, 2023

The FDA announced it has approved Adzynma as prophylactic or on-demand enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura.

Source: hcplive.com
Related Topics:
Peter MarksSperor CatalandWexner Medical CenterCongress SpotlightOhio State UniversityUs Thrombotic Microangiopathy AllianceOhio State University Speror CatalandDrug AdministrationTakeda PharmaceuticalsRare Pediatric Disease Priority Review VoucherPriority ReviewFast TrackBiologics EvaluationFirst TreatmentRare Inherited Blood ClottingPivotal PhaseCongenital Thrombotic Thrombocytopenic PurpuraOnly RecombinantReplacement TherapyThrombotic Thrombocytopenic PurpuraOn DemandEnzyme Replacement Therapy